Abstract and Introduction
Ceftaroline was approved by the Food and Drug Administration (FDA) on November 1, 2010 for adults with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by susceptible bacteria. On May 31, 2016, the FDA extended the approval to include children 2 months of age and older.[1,2] Ceftaroline offers the advantage of a broad spectrum of activity, with efficacy against SSSI caused by methicillin-resistant Staph. aureus (MRSA) and other difficult to treat infections, in addition to a relatively mild adverse effect profile. A number of recent papers describe the studies that were done to support the FDA indication for use in infants, children, and adolescents. These papers, as well as new reviews of the drug and case reports of its adverse effect profile, add to our understanding of the role for this agent in the treatment of pediatric infections.
Pediatr Pharm. 2017;23(6) © 2017 University of Virginia